Sanqi Qushi Granule Alleviates Proteinuria and Podocyte Damage in NS Rat: A Network Pharmacology Study and in vivo Experimental Validation
Lijuan Wang,Huoliang Liu,Yi Wang,XiaoFan Hong,Xiaoyan Huang,Miaoru Han,Dan Wang,Wenjun Shan,Ping Li,Haowen Gu,Bo Liu,Kun Bao
DOI: https://doi.org/10.2147/DDDT.S403617
2023-06-19
Abstract:Lijuan Wang, 1, &ast Huoliang Liu, 2, &ast Yi Wang, 1 XiaoFan Hong, 1 Xiaoyan Huang, 1, 3, 4 Miaoru Han, 1 Dan Wang, 1 Wenjun Shan, 1 Ping Li, 1, 3 Haowen Gu, 1 Bo Liu, 3, 5 Kun Bao 1, 3, 4, 6 1 Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China; 2 The Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China; 3 State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, People's Republic of China; 4 Guangdong-Hong Kong-Macau Joint Laboratory on Chinese Medicine and Immune Disease Research, Guangzhou, People's Republic of China; 5 Guangzhou Key Laboratory of Chirality Research on Active Components of Traditional Chinese Medicine, Guangzhou, People's Republic of China; 6 Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Disease, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Bo Liu; Kun Bao, Email ; Background: Nephrotic syndrome (NS) and its numerous complications remain the leading causes of morbidity and mortality globally. Sanqi Qushi granule (SQG) is clinically effective in NS. However, its potential mechanisms have yet to be elucidated. Methods: A network pharmacology approach was employed in this study. Based on oral bioavailability and drug-likeness, potential active ingredients were picked out. After acquiring overlapping targets for drug genes and disease-related genes, a component-target-disease network and protein–protein interaction analysis (PPI) were constructed using Cytoscape, followed by GO and KEGG enrichment analyses. Adriamycin was injected into adult male Sprague-Dawley (SD) rats via the tail vein to establish NS model. Kidney histology, 24-hr urinary protein level, creatinine (Cr), blood urea nitrogen (BUN), triglyceride (TG), total cholesterol (TC), and low-density lipoprotein (LDL-C) level were assessed. Western blotting, immunohistochemistry, and TUNEL staining were applied. Results: In total, 144 latent targets in SQG acting on NS were screened by a network pharmacology study, containing AKT, Bax, and Bcl-2. KEGG enrichment analysis suggested that PI3K/AKT pathway was enriched primarily. In vivo validation results revealed that SQG intervention ameliorated urine protein level and podocyte lesions in the NS model. Moreover, SQG therapy significantly inhibited renal cells apoptosis and decreased the ratio of Bax/Bcl-2 protein expression. Moreover, we found that Caspase-3 regulated the PI3K/AKT pathway in NS rats, which mediated the anti-apoptosis effect. Conclusion: By combining network pharmacology with experimental verification in vivo, this work confirmed the treatment efficacy of SQG for NS. SQG protected podocyte from injury and inhibited kidney apoptosis in NS rats via the PI3K/AKT pathway at least partially. Keywords: Sanqi Qushi granule, nephrotic syndrome, podocyte injury, kidney apoptosis, network pharmacology, PI3K/AKT pathway Nephrotic syndrome (NS) manifests a range of clinical conditions of massive proteinuria, edema, hypoproteinemia, and hyperlipidemia. 1 Patients with NS are generally more susceptible to hypertension, thrombotic events, and serious infections. 2 Prednisone is often the first-line therapy for NS. 3 Management of NS is very challenging because 10%–20%of patients develop steroid-resistant nephrotic syndrome (SRNS). 3 Moreover, an overwhelming majority of individuals with SRNS progress to Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD) within a few years. 2,4 Currently, there is no specific treatment to curb disease progression into ESRD. 2 Hence, it is urgent to develop effective drugs for NS. Sanqi Qushi Granule (SQG) is derived from Sanqi oral solution, which is a hospital preparation for clinical use in Guangdong Provincial Hospital of Chinese Medicine. 5 Our group confirmed that Sanqi oral solution could exert protective effects in podocyte and mitigate proteinuria. 6,7 Further, the Sanqi Qushi Granule was tolerable, and clinically effective in lowering proteinuria for individuals with NS. However, the underly -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal